bumetanide has been researched along with Familial Hypokalemic Periodic Paralysis in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the hypothesis that inhibition of the Na-K-2Cl transporter with bumetanide will reduce the susceptibility to decreases in muscle force in a mouse model of hypokalemic periodic paralysis (HypoPP)." | 7.79 | Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. ( Cannon, SC; Mi, W; Wu, F, 2013) |
| "To test the hypothesis that inhibition of the Na-K-2Cl transporter with bumetanide will reduce the susceptibility to decreases in muscle force in a mouse model of hypokalemic periodic paralysis (HypoPP)." | 3.79 | Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. ( Cannon, SC; Mi, W; Wu, F, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, F | 2 |
| Mi, W | 2 |
| Cannon, SC | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol[NCT02582476] | Phase 2 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Terminated (stopped due to Slow enrolment and end of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for bumetanide and Familial Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis.
Topics: Animals; Bumetanide; Female; Gene Knock-In Techniques; Hypokalemic Periodic Paralysis; Male; Mice; M | 2013 |
Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
Topics: Acetazolamide; Animals; Arginine; Bumetanide; Calcium Channels, L-Type; Carbonic Anhydrase Inhibitor | 2013 |